|
Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia Clinical research trials and Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia. Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia clinical trial. Human subjects often receive the most effective healthcare possible for their Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia  Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia
Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia
For Condition: Healthy,Schizophrenia
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: The purpose of this study is to understand the role of genetics in the development of childhood-onset schizophrenia (COS). Early studies of COS have concentrated on the relationship between COS and adult-onset schizophrenia (AOS). Recent COS studies, however, focus more on inherited risk factors. Evidence suggests that some individuals with COS have genetic abnormalities. This study will evaluate individuals with COS and AOS along with their first-degree relatives to determine whether risk factors for developing COS are genetic and whether genetic risk factors are more prevalent in individuals with COS than in those with AOS. Control groups of healthy volunteers for COS and AOS participants will also be evaluated. Study assessments will include psychiatric, neuropsychological, and genetic tests.
Details: A study of children and adolescents (current N=48) with very early onset by age 12 (COS) of DSM-III-R defined schizophrenia with (97-M-0126) is examining the clinical, neurobiological, early neurodevelopmental, genetic, and clinical drug response characteristics of these cases. Earlier studies have documented the continuity between COS and adult onset cases (See Jacobsen and Rapoport, 1998 for review). The focus has now shifted to increasing the sample size and evaluation of familial risk factors including: psychiatric diagnoses of family members; smooth pursuit eye movements; neuropsychological tests deficits, and obtaining blood for cell lines for genetic studies (family members only, this is also covered under 96-M-0060, Dr. Ellen Sidransky). A study of obstetrical records of COS probands indicated no increase in adverse pre or perinatal events for these cases compared with obstetrical records of their siblings (Nicolson et al submitted). In contrast, several findings point to increased risk for these probands. To date, a total of 5 (10.4%) COS subjects were found to have previously unknown cytogenetic abnormalities (Microdeletion of 22q11 (3 cases), (Usiskin et al, submitted), Mosaic 45X0 (one case) (Kumra et al, 1998) and balanced 1:7 translocation (Gordon et al 1994). The study of first degree relatives of these very rare cases addresses the hypothesis that risk factors, most probably genetic, are increased in immediate family members relative both to community controls and to the relatives of patients with chronic, treatment resistant, adult-onset schizophrenia (AOS). A second hypothesis is that COS familial risk factors show significant relationship to the developmental delays/abnormalities being observed in the COS probands. As a total of 50 additional COS subjects will be studied over the next 5 years, the pediatric control sample for the probands will also be increased, determined by the need to have concurrent measures for patients and controls to maintain measurement validity. Thus a total of 600 additional subjects are to be studied including 50 controls for COS probands, 150 COS relatives, 150 controls for COS relatives, and 250 relatives of adult onset schizophrenics (AOS).
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Inclusion criteria for healthy controls will continue to be: Ages 6-70. Evidence of normal developmental history and normal functioning. Inclusion criteria for relatives of probands will continue to be: Ages 6-65. Evidence of blood relationship to proband with a disorder under study, with usual selection of first-degree relatives. EXCLUSION CRITERIA: Exclusion criteria for community controls are: Evidence of medical or neurological disease. Diagnosis of schizophrenia or schizoaffective disorder in subject or in his/her first degree relatives by history, clinical interview, or by structured, diagnostic psychiatric interview. Exclusion criteria for relatives of probands: Absence of consent on the part of the proband or parent(s) of proband to contact relatives. Absence of signed consent or assent by relative(s) to participate.
Total Enrollment: 1975
Location and Contact Information:
National Institute of Mental Health (NIMH) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Maureen Tobin 3014354518
Additional Information:
Study ID Numbers: 840050; 84-M-0050
Study Start Date: March 19, 1984
Record last reviewed: February 20, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001198
Other Healthy Studies:
1. Imaging of Brain Receptors in Healthy Volunteers and in Patients with Schizophrenia
2. Schizophrenia Study
3. Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome
4. 3 Fixed Dosages of Extended Release OROS Paliperidone and Olanzapine in the Treatment of Subjects with Schizophrenia
5. The Efficacy and Safety of Risperidone in the Treatment of Adolescents with Schizophrenia
Related Studies:
Other Healthy Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia
|
|
|
|
|
|
|
|
